transcript   Transcript

Sandoz v. Amgen: Supreme Court Avoids “Patent Dance” Questions and Gives Biosimilar Applicants Early Market Entry

Recorded on: Jun. 30, 2017
Running Time: 01:01:30

Full Transcript:

If you are a Privileged Member, just log in and start reading now! If you are not a Privileged Member, please click here to learn how unlimited access to PLI programs may be right for you and your firm.

To access the streaming media of this presentation, please purchase the corresponding seminar segment.

Taken from the briefing Sandoz v. Amgen: Supreme Court Avoids “Patent Dance” Questions and Gives Biosimilar Applicants Early Market Entry recorded June 2017 in New York.

The Supreme Court rendered its decision in Sandoz v. Amgen interpreting for the first time the provisions of the Biologic Products Competition and Innovation Act (BPCIA). In what was certainly a disappointment, the Court avoided the question of whether a biosimilar applicant (BA) is required to disclose to the reference product sponsor (i.e., the innovator biologic drug maker, RPS) either its application to the FDA for approval or any relevant manufacturing details (known as the “patent dance”), despite the statute’s language apparently mandating disclosure. On this issue the Court merely held that the statute provides no injunction remedy to an RPS if a BA refuses to participate in the “patent dance.” The issue was remanded to the Federal Circuit to determine whether California state law (unfair competition) provides an injunctive remedy. On the other issue before it, whether a BA could only give the mandated 180-day Notice of Marketing after FDA approval, the Court reversed the Federal Circuit and held notice could be given at any time.

Lecture Topics  [01:01:30]

This Briefing was conducted by Kevin E. Noonan, Ph.D. of McDonnell Boehnen Hulbert & Berghoff LLP. Specific topics covered will include:

  • A review of the provisions of the statute related to patent litigation and marketing approval
  • Statutory construction of the disclosure and marketing provisions
  • The consequences for RPSs regarding remand based on state law and the interplay between individual states’ unfair competition laws and Federal preemption under the BPCIA
  • Uncertainty regarding marketing decisions and timing, as well as choice of patents to enforce by early (pre-approval) marketing notice and the implications on the litigation regime in the BPCIA
  • The impact of these decisions on the biosimilar process and future patent litigations
  • Possibilities for Congressional revisions to the statute to address the Supreme Court’s decision

Presentation Material

    Kevin E. Noonan, Ph.D.
  • The Evolving World of Biosimilars Litigation
    Kevin E. Noonan, Ph.D.
Kevin E Noonan, Ph.D. ~ McDonnell Boehnen Hulbert & Berghoff LLP
Transcript FAQ's
  • How Can I Access Transcripts?
    You must be a Member in good standing.

  • Can I access the Video?
    Yes, you can access the video if you have the Adobe Flash plugin installed. Click on the video camera icon when you mouse over each paragraph. The media will begin playback at that point.

  • Can I get CLE credit for reading the transcript?
    No, CLE credit cannot be earned for reading a transcript. CLE credit is issued only for verified attendance while watching a web program. If seeking credit, please verify the program's eligibility for credit and expiration date in your jurisdiction on the web segment launch page before commencing the program.

  • twitter
  • LinkedIn
  • YouTube
  • RSS

All Contents Copyright © 1996-2018 Practising Law Institute. Continuing Legal Education since 1933.

© 2018 PLI PRACTISING LAW INSTITUTE. All rights reserved. The PLI logo is a service mark of PLI.